MX349530B - Metodos para producir particulas de virus con glucosilacion simplificada de proteinas de superficie. - Google Patents

Metodos para producir particulas de virus con glucosilacion simplificada de proteinas de superficie.

Info

Publication number
MX349530B
MX349530B MX2013004996A MX2013004996A MX349530B MX 349530 B MX349530 B MX 349530B MX 2013004996 A MX2013004996 A MX 2013004996A MX 2013004996 A MX2013004996 A MX 2013004996A MX 349530 B MX349530 B MX 349530B
Authority
MX
Mexico
Prior art keywords
methods
production
virus particles
surface proteins
glycosylation
Prior art date
Application number
MX2013004996A
Other languages
English (en)
Other versions
MX2013004996A (es
Inventor
Huey Wong Chi
Ma Che
Chieh Tseng Yung
Original Assignee
Acad Sinica *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46024856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX349530(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acad Sinica * filed Critical Acad Sinica *
Publication of MX2013004996A publication Critical patent/MX2013004996A/es
Publication of MX349530B publication Critical patent/MX349530B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01096—Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a métodos para producción de partículas de virus con glucosilación simplificada en proteínas estructurales o de superficie. Cuando se utilizan como objetivos para producción de vacunas, la naturaleza conservada de dichos sitios genera vacunas que son más sensibles a mutaciones víricas. Se describe el uso de inhibidores de glucosilación para producción de virus con perfiles de glucosilación simplificados. Se proporciona una descripción de ejemplo de los virus de la influenza y métodos para producción de partículas de virus de influenza monoglucosilada. Se proporcionan métodos para producción de formas monoglucosiladas de virus de influenza A, NIBRG-14 (H5N1).
MX2013004996A 2010-11-04 2011-11-04 Metodos para producir particulas de virus con glucosilacion simplificada de proteinas de superficie. MX349530B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41025710P 2010-11-04 2010-11-04
PCT/US2011/059449 WO2012061776A1 (en) 2010-11-04 2011-11-04 Methods for producing virus particles with simplified glycosylation of surface proteins

Publications (2)

Publication Number Publication Date
MX2013004996A MX2013004996A (es) 2014-02-27
MX349530B true MX349530B (es) 2017-08-02

Family

ID=46024856

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004996A MX349530B (es) 2010-11-04 2011-11-04 Metodos para producir particulas de virus con glucosilacion simplificada de proteinas de superficie.

Country Status (17)

Country Link
US (2) US9403878B2 (es)
EP (1) EP2635693B1 (es)
JP (2) JP6166178B2 (es)
KR (2) KR101927421B1 (es)
CN (2) CN108165534A (es)
AU (2) AU2011323141B2 (es)
BR (1) BR112013011198B1 (es)
CA (2) CA2854619C (es)
CL (1) CL2013001219A1 (es)
CO (1) CO6781543A2 (es)
DK (1) DK2635693T3 (es)
ES (1) ES2831256T3 (es)
IL (1) IL226143B (es)
MX (1) MX349530B (es)
RU (1) RU2607452C2 (es)
TW (1) TWI537385B (es)
WO (1) WO2012061776A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103200961B (zh) 2009-03-27 2017-10-27 中央研究院 抗病毒免疫的方法和组合物
TWI537385B (zh) 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法
US20180128545A1 (en) * 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
WO2023238756A1 (ja) * 2022-06-07 2023-12-14 国立大学法人 東京大学 ウイルス粒子検出方法、情報処理装置及びウイルス粒子検出プログラム

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953592A (en) * 1973-09-27 1976-04-27 Recherche Et Industrie Therapeutiques (R.I.T.) Live influenza virus vaccines and preparation thereof
US4318903A (en) * 1978-07-12 1982-03-09 Smithkline-Rit Live influenza virus vaccine and the preparation thereof
US4338296A (en) * 1979-10-16 1982-07-06 Smithkline-Rit Influenza virus and process of producing a vaccine therefrom
JPS62501263A (ja) 1984-11-29 1987-05-21 スクリツプス　クリニツク　アンド　リサ−チ　フアウンデ−シヨン 脱グリコシル化ウイルス糖タンパク質に関連するポリペプチド類および抗体
WO1987005330A1 (en) * 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
NZ224422A (en) 1987-05-05 1990-11-27 Molecular Eng Ass Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
US6103238A (en) 1992-03-13 2000-08-15 President And Fellows Of Harvard College Selectively deglycosylated human immunodeficiency virus type 1 envelope vaccines
AU698878B2 (en) 1993-11-04 1998-11-12 Genimmune N.V. Immunodominant human T-cell epitopes of hepatitis C virus
US20020045594A1 (en) 1997-02-14 2002-04-18 Merck & Co., Inc. Polynucleotide vaccine formulations
US6908617B1 (en) 1997-11-10 2005-06-21 Dana-Farber Cancer Institute, Inc. Glycosylated modified primate lentivirus envelope polypeptides
AU4537100A (en) 1999-05-12 2000-12-05 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
FR2799974B1 (fr) 1999-10-25 2001-11-30 Aventis Pasteur Complexe deglycosyle proteine env/cd4 et son utilisation pour la vaccination contre le vih
WO2001074386A2 (en) * 2000-04-03 2001-10-11 The University Of Pittsburgh - Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
CA2411968C (en) 2000-06-30 2009-12-15 Flanders Interuniversity Institute For Biotechnology (Vib) Protein glycosylation modification in pichia pastoris
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
CA2468295C (en) * 2001-11-28 2010-08-03 Neose Technologies, Inc. Glycoprotein remodeling using endoglycanases
US20030124652A1 (en) * 2001-12-21 2003-07-03 Novazyme Pharmaceuticals, Inc. Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells
US7442375B2 (en) 2002-12-13 2008-10-28 Case Western Reserve University Compositions of beta-defensin inducing agents
CN103555670B (zh) * 2004-12-23 2015-08-12 米迪缪尼有限公司 用于病毒增殖的非致瘤性mdck细胞系
CA2601797A1 (en) * 2005-03-16 2006-09-21 University Of Oxford Mannose immunogens for hiv-1
RU2283139C1 (ru) * 2005-03-21 2006-09-10 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Способ получения антигенов для вакцины против вирусов гриппа
US20080118529A1 (en) 2005-07-13 2008-05-22 Gebbink Martijn Frans Ben Gera Adjuvation Through Cross -Beta Structure
CA2628725A1 (en) 2005-11-15 2007-05-31 Glycofi, Inc. Production of glycoproteins with reduced o-glycosylation
ES2310072B1 (es) 2005-12-23 2009-11-16 Proyecto De Biomedicina Cima, S.L. Nuevos peptidos determinantes antigenicos t colaboradores (/dth).
TW200745158A (en) 2006-03-07 2007-12-16 Vaxinnate Corp Compositions that include hemagglutinin, methods of making and methods of use thereof
CA2647632C (en) * 2006-03-27 2017-06-27 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
US7507411B2 (en) 2006-06-23 2009-03-24 University Of Saskatchewan Attenuated influenza NS1 variants
WO2007150054A2 (en) 2006-06-24 2007-12-27 Mrugesh Shah Immunogenic compositions having altered glycosylations
JP2010500880A (ja) 2006-08-14 2010-01-14 マサチューセッツ・インスティテュート・オブ・テクノロジー ヘマグルチニンポリペプチド、ならびにヘマグルチニンポリペプチドに関連する試薬および方法
WO2008112017A2 (en) 2006-10-10 2008-09-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healtand Human Services Avian influenza vaccine
CA2676028A1 (en) 2007-01-18 2008-11-27 Samuel Bogoch Methods of determining lethality of pathogens and malignancies involving replikin peak genes
US7928068B2 (en) 2007-01-31 2011-04-19 New York University Methods for using GEP, a chondrogenic growth factor and target in cartilage disorders
CN103200961B (zh) * 2009-03-27 2017-10-27 中央研究院 抗病毒免疫的方法和组合物
BRPI1015019A2 (pt) * 2009-04-20 2018-02-14 Pfizer controle de glicosilação de proteína e composições e métodos relacionada a ele.
WO2011044152A1 (en) * 2009-10-05 2011-04-14 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer Protection against pandemic and seasonal strains of influenza
TWI537385B (zh) 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法

Also Published As

Publication number Publication date
TW201307560A (zh) 2013-02-16
EP2635693A4 (en) 2014-05-07
US9403878B2 (en) 2016-08-02
JP2014500012A (ja) 2014-01-09
EP2635693A1 (en) 2013-09-11
BR112013011198B1 (pt) 2022-03-15
AU2016204276B2 (en) 2017-10-26
TWI537385B (zh) 2016-06-11
AU2011323141B2 (en) 2016-04-07
CA3147075A1 (en) 2012-05-10
KR101927421B1 (ko) 2018-12-10
CN108165534A (zh) 2018-06-15
KR20130115292A (ko) 2013-10-21
ES2831256T3 (es) 2021-06-08
CL2013001219A1 (es) 2014-04-04
AU2016204276A1 (en) 2016-07-14
JP6773513B2 (ja) 2020-10-21
CA2854619A1 (en) 2012-05-10
US20140011188A1 (en) 2014-01-09
AU2011323141A1 (en) 2013-06-27
RU2013125590A (ru) 2014-12-10
JP6166178B2 (ja) 2017-07-19
US9920347B2 (en) 2018-03-20
JP2017031204A (ja) 2017-02-09
IL226143B (en) 2020-04-30
RU2607452C2 (ru) 2017-01-10
WO2012061776A1 (en) 2012-05-10
MX2013004996A (es) 2014-02-27
CO6781543A2 (es) 2013-10-31
KR102156209B1 (ko) 2020-09-17
DK2635693T3 (da) 2020-12-21
IL226143A0 (en) 2013-06-27
EP2635693B1 (en) 2020-10-07
CA2854619C (en) 2022-02-01
CN103476942A (zh) 2013-12-25
BR112013011198A2 (pt) 2016-07-05
US20160348144A1 (en) 2016-12-01
KR20180132981A (ko) 2018-12-12

Similar Documents

Publication Publication Date Title
EP4349404A3 (en) Respiratory virus vaccines
EP4233898A3 (en) Influenza mrna vaccines
MX2018004916A (es) Vacuna contra el virus de la influenza de amplio espectro.
AU2014310935B2 (en) Combination vaccine
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
HK1214509A1 (zh) 穏定的人類免疫缺陷病毒 包膜蛋白基因 三聚體疫苗及其使用方法
MX2021001053A (es) Vacunas contra virus de la influenza y sus usos.
MX354750B (es) PARTÍCULAS PSEUDO-VIRALES (PPVs) QUE COMPRENDEN GLICOPROTEÍNAS DEL VIRUS DE LA RABIA.
AU2016204276A1 (en) Methods for producing virus particles with simplified glycosylation of surface proteins
EP3143144A4 (en) VIRUS LIKE VESICLES (VLVs) BASED VACCINES TO PREVENT OR TREAT CHRONIC HEPATITIS B VIRUS (HBV) INFECTION
MX360470B (es) Uso de inhibidores de oxido nitrico sintasa inducible para aumentar el rendimiento viral en el cultivo.
NZ739260A (en) Inactivated canine influenza vaccines and methods of making and uses thereof
BR112012022939A2 (pt) composição farmacêutica para uso em um método de imunização de um indivíduo em necessidade do mesmo contra um vírus influenza
CL2016003181A1 (es) Vacunas de virus varicela zóster inactivado, métodos de producción y uso de las mismas (divisional de sol. n° 360-13).
MX363464B (es) Vacunas contra influenza h5.
EP3699186A4 (en) H3N2 INFLUENZA VIRUS MUTANT HEMAGGLUTININ MUTANT AND ITS USE
WO2012024283A3 (en) Universal influenza a vaccines
MX360161B (es) Proceso para preparar compuestos antiviricos.
EP3599247A3 (en) Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
WO2012162342A3 (en) Influenza vaccines containing modified adenovirus vectors
MX2015010763A (es) Proteinas h5 del virus de la gripe h5n1 para uso como un medicamento.
IN2011CH03893A (es)
SG11201400629UA (en) An in-vitro process for the quick determination of the infection status of an infection with an influenza virus type
WO2017011620A3 (en) Methods and compositions related to increasing the fidelity of influenza a virus for vaccine development
WO2013041877A3 (en) Influenza virus mutant expressing a haemagglutinin protein without functional signal sequence for use as vaccine

Legal Events

Date Code Title Description
FG Grant or registration